- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07850141
Prospective Registry of Exposure to Gepotidacin (PREG)
Prospective Registry of Exposure to Gepotidacin (PREG): a Prospective Registry of Women and Their Offspring Exposed to Gepotidacin During Pregnancy
The purpose of this study is to monitor pregnancies exposed to gepotidacin and to evaluate possible teratogenic effects or birthweight-lowering effects of this medication relative to the primary outcomes of major congenital malformations (MCMs) and small for gestational age (SGA), as well as to evaluate secondary maternal, fetal, and infant outcomes.
Przegląd badań
Status
Interwencja / Leczenie
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: US GSK Clinical Trials Call Center
- Numer telefonu: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Kopia zapasowa kontaktu do badania
- Nazwa: EU GSK Clinical Trials Call Center
- Numer telefonu: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Pregnant participants with uncomplicated urinary tract infection who are exposed to gepotidacin or standard-of-care antibiotics during the relevant exposure window.
Opis
Inclusion Criteria:
For Both cohorts:
- Participants with aged 15 to 50 years
- United States resident
- Currently pregnant
- Participants personally signed and dated informed consent document or, upon waiver of written consent by the relevant Institutional review board (IRB), verbal consent indicating that the participant (or a legally acceptable representative) has been informed of all pertinent aspects of the study
- Authorization and contact information for the reporter (e.g., participant, maternal/infant Health care provider (HCP), prescriber) to allow for follow-up
Exposed cohort:
• Exposed to gepotidacin at any time during pregnancy or the relevant exposure window
Comparator cohort:
- Diagnosis of and treatment for uUTI at any time during pregnancy or the relevant comparator product exposure window
- Exposed to one or more American College of Obstetricians and Gynecologists (ACOG)-recommended treatments for acute cystitis at any time during pregnancy or the relevant comparator product exposure window
Exclusion Criteria:
For Both cohorts:
• Diagnosis of known MCMs for the index pregnancy prior to enrollment
Exposed cohort:
• None
Comparator cohort:
• Exposure to gepotidacin at the time of enrollment
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: COHORT
- Perspektywy czasowe: PROSPECTIVE
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Exposed cohort
Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to gepotidacin during the relevant exposure window |
Not Applicable since Observational Study
Inne nazwy:
|
|
Comparator cohort
Pregnant participants with uncomplicated urinary tract infection (uUTI) who are exposed to standard-of-care antibiotics during the relevant exposure window |
Not Applicable since Observational Study
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of infants with major congenital malformations (MCMs)
Ramy czasowe: At pregnancy outcome, with follow-up through 12 months after delivery
|
An abnormality of body structure or function that is present at birth, is of prenatal origin (i.e., birth defect), has significant medical, social, or cosmetic consequences for the affected individual, and typically requires medical intervention. |
At pregnancy outcome, with follow-up through 12 months after delivery
|
|
Number of infants with small-for-gestational-age births (SGA)
Ramy czasowe: At live birth
|
A newborn infant whose birth weight is less than (<) 10th percentile for sex and gestational age using standard growth charts for full- and preterm live-born infants. |
At live birth
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Number of infants with minor congenital malformations
Ramy czasowe: At live Birth, with follow-up up through 12 months of age
|
An anomaly or abnormality of body structure that is present at birth, is of prenatal origin (i.e., birth defect), poses no significant health problem in the neonatal period, and tends to have limited social or cosmetic consequences for the affected individual. |
At live Birth, with follow-up up through 12 months of age
|
|
Number of participants (pregnant women) with pregnancy termination
Ramy czasowe: From date of conception (DOC) to <20 gestational weeks
|
A voluntary fetal loss or interruption of pregnancy that occurs for any reason, including but not limited to for the preservation of maternal health or because of fetal abnormalities. |
From date of conception (DOC) to <20 gestational weeks
|
|
Number of participants (pregnant women) with spontaneous abortions (SAB)
Ramy czasowe: From date of conception (DOC) to <20 gestational weeks
|
An involuntary fetal loss or the expulsion of the products of conception occurring at less than (<) 20 gestational weeks. |
From date of conception (DOC) to <20 gestational weeks
|
|
Number of participants (pregnant women) with stillbirths
Ramy czasowe: From 20 weeks' gestation to pregnancy outcome
|
Stillbirth is defined by the American College of Obstetricians and Gynecologists (ACOG), an involuntary fetal loss occurring at greater than or equal to (>=) 20 weeks of gestation, or, if gestational age is unknown, a fetus weighing >=350 grams. |
From 20 weeks' gestation to pregnancy outcome
|
|
Number of participants (pregnant women) with preeclampsia
Ramy czasowe: From 20 weeks' gestation to pregnancy outcome
|
Preeclampsia is disorder of pregnancy associated with new-onset hypertension, which occurs most often after 20 weeks of gestation and frequently near term, and proteinuria, or, in the absence of proteinuria, it is defined as new-onset hypertension with the new onset of any of the following: Thrombocytopenia: platelet count <100,000/milliliter (mL). Renal insufficiency: serum creatinine concentrations >1.1 milligram per deciliter (mg/dL) or a doubling of the serum creatinine concentration in the absence of other renal disease. Impaired liver function: elevated blood concentrations of liver transaminases to twice the normal concentration. Pulmonary edema. New-onset headache unresponsive to medication and not accounted for by alternative diagnoses or visual symptoms |
From 20 weeks' gestation to pregnancy outcome
|
|
Number of participants (pregnant women) with eclampsia
Ramy czasowe: From 20 weeks' gestation to pregnancy outcome
|
New-onset tonic-clonic, focal, or multifocal seizures in the absence of other causative conditions such as epilepsy, cerebral arterial ischemia and infarction, intracranial hemorrhage, or drug use. |
From 20 weeks' gestation to pregnancy outcome
|
|
Number of participants (pregnant women) with gestational hypertension
Ramy czasowe: From 20 weeks' gestation to pregnancy outcome
|
Blood pressure greater than 140 millimeter of mercury (mmHg) systolic or 90 mmHg diastolic on 2 separate occasions at least 4 hours apart after 20 weeks of pregnancy when previous blood pressure was normal. |
From 20 weeks' gestation to pregnancy outcome
|
|
Number of participants (pregnant women) with gestational diabetes
Ramy czasowe: At pregnancy outcome
|
Any degree of glucose intolerance with onset or first recognition during pregnancy. |
At pregnancy outcome
|
|
Number of participants (pregnant women) with preterm births
Ramy czasowe: At live birth, if occurring before 37 gestational weeks
|
Preterm birth is defined as a live birth occurring at <37 gestational weeks. |
At live birth, if occurring before 37 gestational weeks
|
|
Number of infants with postnatal growth deficiency
Ramy czasowe: At 4 and 12 months of infant age
|
Weight, length, or head circumference in <10th percentile for sex and chronological age using standard growth charts |
At 4 and 12 months of infant age
|
|
Number of infants with developmental delay
Ramy czasowe: At 4 and 12 months of infant age
|
Failure to achieve the developmental milestones for chronological age, as defined by the Centers for Disease Control and Prevention. |
At 4 and 12 months of infant age
|
Współpracownicy i badacze
Sponsor
Śledczy
- Dyrektor Studium: GSK Clinical Trials, GlaxoSmithKline
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Szacowany)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu moczowo-płciowego
- Choroby narządów płciowych
- Procesy patologiczne
- Choroby układu moczowo-płciowego u mężczyzn
- Choroby Urologiczne
- Choroby układu moczowo-płciowego kobiet
- Choroby układu moczowo-płciowego kobiet i powikłania ciąży
- Atrybuty choroby
- Infekcje
- Choroby zakaźne
- Stany patologiczne, oznaki i objawy
- Choroby przenoszone drogą płciową
- Infekcje dróg moczowych
- Techniki śledcze
- Metody
- Obserwacja
Inne numery identyfikacyjne badania
- 300392
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .